Schroder Investment Management Group Sells 26,731 Shares of Repligen Co. (RGEN)

Schroder Investment Management Group lowered its position in shares of Repligen Co. (NASDAQ:RGEN) by 5.2% in the second quarter, Holdings Channel reports. The fund owned 483,227 shares of the biotechnology company’s stock after selling 26,731 shares during the period. Schroder Investment Management Group’s holdings in Repligen were worth $22,615,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Meadow Creek Investment Management LLC raised its position in shares of Repligen by 21.7% during the second quarter. Meadow Creek Investment Management LLC now owns 7,840 shares of the biotechnology company’s stock worth $369,000 after acquiring an additional 1,400 shares during the last quarter. Legal & General Group Plc raised its position in shares of Repligen by 2.0% during the first quarter. Legal & General Group Plc now owns 77,094 shares of the biotechnology company’s stock worth $2,771,000 after acquiring an additional 1,527 shares during the last quarter. Profund Advisors LLC raised its position in shares of Repligen by 29.2% during the first quarter. Profund Advisors LLC now owns 7,174 shares of the biotechnology company’s stock worth $260,000 after acquiring an additional 1,620 shares during the last quarter. Brown Advisory Inc. raised its position in shares of Repligen by 24.0% during the second quarter. Brown Advisory Inc. now owns 8,640 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 1,673 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its position in shares of Repligen by 30.8% during the second quarter. Envestnet Asset Management Inc. now owns 8,021 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 1,891 shares during the last quarter. Institutional investors own 92.50% of the company’s stock.

In other Repligen news, CEO Anthony Hunt sold 27,566 shares of the business’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $57.71, for a total value of $1,590,833.86. Following the completion of the transaction, the chief executive officer now directly owns 255,017 shares of the company’s stock, valued at $14,717,031.07. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Thomas F. Ryan, Jr. sold 2,366 shares of the business’s stock in a transaction dated Wednesday, August 22nd. The shares were sold at an average price of $51.44, for a total value of $121,707.04. Following the completion of the transaction, the director now directly owns 4,988 shares of the company’s stock, valued at $256,582.72. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 88,884 shares of company stock valued at $4,693,683. 1.40% of the stock is owned by insiders.

Shares of Repligen stock opened at $54.01 on Friday. Repligen Co. has a 12 month low of $29.56 and a 12 month high of $58.99. The firm has a market cap of $2.43 billion, a P/E ratio of 78.58, a P/E/G ratio of 4.46 and a beta of 0.69.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). Repligen had a return on equity of 5.05% and a net margin of 13.49%. The company had revenue of $47.73 million for the quarter, compared to analyst estimates of $45.84 million. During the same period last year, the firm earned $0.20 earnings per share. The firm’s revenue for the quarter was up 47.0% on a year-over-year basis. Analysts anticipate that Repligen Co. will post 0.71 EPS for the current year.

A number of equities research analysts recently commented on the company. BidaskClub cut Repligen from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 31st. Zacks Investment Research cut Repligen from a “hold” rating to a “sell” rating in a research note on Tuesday, August 7th. Citigroup lifted their price objective on Repligen from $45.00 to $56.00 and gave the stock a “buy” rating in a research note on Friday, July 20th. ValuEngine raised Repligen from a “hold” rating to a “buy” rating in a research note on Thursday, June 28th. Finally, HC Wainwright assumed coverage on Repligen in a research note on Wednesday, September 26th. They set a “neutral” rating and a $49.00 price objective for the company. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $51.86.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Read More: Risk Tolerance

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply